Innate-immune crosstalk orchestrates T cell-mediated rejection in kidney transplants - Top-Institutions - MDSpire

Innate-immune crosstalk orchestrates T cell-mediated rejection in kidney transplants

  • By

  • Yuyun Hu

  • Zhiqiang Chen

  • Yujun Liang

  • Zhixuan Wu

  • Yijian Zhang

  • Junyu Guo

  • Chunqiang Dong

  • Guanmiao Chen

  • Michael Williams

  • Emily Johnson

  • Min He

  • Wei Du

  • Boqian Wang

  • July 7, 2026

  • 0 min

Share

Top Institutions in Pathology

Brief introduction explaining scope and methodology.

  • #1

    NewYork-Presbyterian Hospital–Columbia University Irving Medical Center
    NewYork-Presbyterian Hospital–Columbia University Irving Medical Center

    New York, NY

    Key Differentiators

    • Transplant Surgery

  • #2

    Northwestern Medicine–Northwestern Memorial Hospital
    Northwestern Medicine–Northwestern Memorial Hospital

    Chicago, IL

    Key Differentiators

    • Transplant Surgery

  • #3

    Eurotransplant
    Eurotransplant

    Leiden, Netherlands

    Key Differentiators

    • Transplant Surgery

  • #4

    University of California, San Francisco
    University of California, San Francisco

    San Francisco, CA

    Key Differentiators

    • Transplant Surgery

  • #5

    German Transplantation Society
    German Transplantation Society

    Berlin, Germany

    Key Differentiators

    • Transplant Surgery

Original Source(s)

Innate-immune crosstalk orchestrates T cell-mediated rejection in kidney transplants

  • by Yuyun Hu, Zhiqiang Chen, Yujun Liang, Zhixuan Wu, Yijian Zhang, Junyu Guo, Chunqiang Dong, Guanmiao Chen, Michael Williams, Emily Johnson, Min He, Wei Du, Boqian Wang

  • July 7, 2026

Related Content

Reanalysis of the immunological characteristics of scalp psoriasis: a cross-sectional study using Olink proteomics

Can AI Outpace Infectious Diseases?

Leading experts discuss the opportunities, challenges, and future applications of AI in infectious disease testing

FDA Expands Gene Therapy for Younger Patients

Exagamglogene autotemcel is now indicated for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.